IMVT-1402 durability confirmed in D2T RA, but Sjögren's deprioritized

What happened

Immunovant announced that in the randomized withdrawal period (Period 2) of its potentially registrational D2T RA trial, IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs 75.6% placebo, p=0.0139), providing the first controlled durability evidence for the anti-FcRn antibody. Exploratory analyses showed continued improvement in ACR50 (80.0%) and ACR70 (52.5%) for patients remaining on the 600 mg dose, reinforcing the efficacy signal observed in the open-label lead-in. The company intends to hold FDA discussions later this year to determine the registrational path forward for IMVT-1402 in D2T RA. In contrast, Immunovant stated it is unlikely to further develop IMVT-1402 for Sjögren's disease (SjD) beyond the ongoing Phase 2 trial, citing an evolving competitive landscape and recent data. All other clinical development timelines remain on track, with the company reiterating expectations for topline data in Graves' disease and myasthenia gravis in 2027.

Implication

Investors should view the Period 2 ACR20 maintenance result as a major validation of IMVT-1402's durability in a difficult-to-treat population, moving the stock past the 'open-label only' critique that underpinned the prior WAIT rating. The high placebo response (75.6%) suggests that the treatment effect, while significant, may be modest, and the relatively small sample size warrants caution until full data are presented. The planned FDA discussions are critical; a clear path to a registrational trial or accelerated approval could trigger re-rating, whereas a request for additional studies would temper enthusiasm. The decision to not advance Sjögren's reduces pipeline breadth and removes a potential 2028 catalyst, but it may also be a prudent capital allocation move given competitive developments. With other timelines intact and a strengthened cash position (over $900 million as of March 2026), the risk/reward has improved, though financing needs for a broad development program remain a long-term overhang.

Thesis delta

The thesis has shifted from 'wait for controlled durability' to 'durability confirmed, but registrational path unclear.' The positive RA Period 2 result resolves a key uncertainty and supports the best-in-class ambition, yet the Sjögren's pullback and upcoming FDA feedback mean the stock is not fully de-risked. Overall, the investment thesis strengthens, with a higher probability of success for the RA program and a narrowed focus on core indications.